Charles River Laboratories International, Inc. Common Stock (CRL)
167.70
-10.15 (-5.71%)
NYSE · Last Trade: Nov 5th, 6:14 PM EST
Detailed Quote
Previous Close
177.85
Open
163.29
Bid
150.90
Ask
170.23
Day's Range
160.01 - 170.14
52 Week Range
91.86 - 230.02
Volume
2,827,079
Market Cap
8.45B
PE Ratio (TTM)
-131.02
EPS (TTM)
-1.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
986,111
Chart
About Charles River Laboratories International, Inc. Common Stock (CRL)
Charles River Laboratories International is a global provider of laboratory services that support the pharmaceutical, biotechnology, and medical device industries. The company offers a comprehensive suite of research and development solutions, including essential support for drug discovery, safety assessment, and manufacturing. By providing innovative tools and technologies, as well as expertise in areas such as toxicology and genetic testing, Charles River plays a critical role in advancing biomedical research and helping clients develop and bring new therapies to market efficiently and effectively. Read More
Shares of lab services company Charles River Laboratories (NYSE:CRL)
fell 5.8% in the morning session after the company reported third-quarter results that revealed significant underlying weaknesses.
Stay tuned for the market movements in the S&P500 index on Wednesday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
Lab services company Charles River Laboratories (NYSE:CRL) announced better-than-expected revenue in Q3 CY2025, but sales were flat year on year at $1.00 billion. Its non-GAAP profit of $2.43 per share was 3.9% above analysts’ consensus estimates.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced an update on its Board of Directors’ comprehensive strategic review of the Company’s business and growth prospects. The Board strongly supports the Company’s strategic direction and believes it should continue to focus on strengthening its leading scientific portfolio within its core markets, divesting underperforming or non-core assets, maximizing its financial performance, and maintaining a disciplined approach to capital deployment. To further support this strategy, the Company is taking the following actions to drive long-term shareholder value creation:
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2025. For the quarter, revenue was $1.00 billion, a decrease of 0.5% from $1.01 billion in the third quarter of 2024.
Lab services company Charles River Laboratories (NYSE:CRL)
will be announcing earnings results this Wednesday before market hours. Here’s what you need to know.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Charles River Laboratories International, Inc. (“Charles River” or the “Company”) (NYSE: CRL).
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to shareholders.
Charles River Laboratories International, Inc. (NYSE: CRL) and The Francis Crick Institute (Crick) today announced a new collaboration around Antibody-Drug Conjugate (ADC) drug discovery and development, leveraging combined strengths to accelerate the development and delivery of next-generation targeted therapies.
Charles River Laboratories International, Inc. (NYSE:CRL) today announced a strategic collaboration with X-Chem, Inc., the pioneer in DNA-encoded library (DEL) technology and a data-driven drug discovery company, to enhance its hit identification (Hit ID) capabilities and accelerate the discovery of novel therapeutics. This partnership enables Charles River clients to access X-Chem’s DEL platform, which features a proprietary library of over 15 billion compounds.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the creation of a global, cross-functional Scientific Advisory Board, led by Dr. Namandjé N. Bumpus, to guide the Company’s strategic focus on New Approach Methodologies (NAMs). NAMs are non-clinical tools that enhance the predictability of efficacy and safety in the development of therapeutics and chemical substances, aiming to reduce reliance on animal testing.
Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2025 financial results on Wednesday, November 5th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 5th, at 9:00 a.m. ET.
The past six months have been a windfall for Charles River Laboratories’s shareholders. The company’s stock price has jumped 60.1%, hitting $170.64 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Charles River Laboratories (NYSE:CRL) and its peers.
Charles River Laboratories International, Inc. (NYSE: CRL) and Toxys today announced a collaboration that offers Charles River’s clients access to ReproTracker®, a state-of-the-art human stem cell-based in vitro assay that rapidly and reliably identifies developmental toxicity hazards of new drugs and chemicals.
Shares of lab services company Charles River Laboratories (NYSE:CRL)
jumped 2.6% in the afternoon session after the stock's positive momentum continued, as Barclays upgraded the company to Overweight from Equal Weight and raised its price target.
Shares of lab services company Charles River Laboratories (NYSE:CRL)
jumped 1.9% in the morning session after Barclays upgraded the company to Overweight from Equal-Weight and raised its price target.
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.
